Webinar recording now available. Recursion CEO Chris Gibson at our March 6 webinar explained the exciting results from Recursion’s Phase II SYCAMORE trial, the first industry-sponsored clinical trial for REC-994, …
Join us Thursday, February 20th at 7 pm ET/4 pm PT for updates to our CCM Clinical Consensus Guidelines and a discussion of the Atorvastatin study results with Dr. Issam…
Join us on January 23rd, at 7 pm ET/4 pm PT for a presentation on “Healing Beyond the Diagnosis: Understanding and Coping with Medical Trauma in Cavernous Malformation.” This session…
Read Alliance to Cure’s Fall 2024 Newsletter Alliance to Cure’s Fall Newsletter highlights our progress towards better treatments and a cure for cavernous malformation. Read the newsletter to learn about…
Recursion’s SYCAMORE trial meets primary endpoint of safety and demonstrates encouraging trends in objective MRI-based exploratory efficacy measures SALT LAKE CITY, Sept. 03, 2024 (GLOBE NEWSWIRE) — Recursion (NASDAQ: RXRX), a leading…
